FY2026 EPS Estimates for Insulet Raised by Leerink Partnrs

Insulet Co. (NASDAQ:PODD - Free Report) - Research analysts at Leerink Partnrs upped their FY2026 EPS estimates for shares of Insulet in a note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky now anticipates that the medical instruments supplier will post earnings of $6.03 per share for the year, up from their prior forecast of $5.62. The consensus estimate for Insulet's current full-year earnings is $3.04 per share.

Several other brokerages have also recently commented on PODD. Raymond James boosted their target price on shares of Insulet from $213.00 to $260.00 and gave the company an "outperform" rating in a research report on Monday. Canaccord Genuity Group boosted their target price on shares of Insulet from $236.00 to $269.00 and gave the company a "buy" rating in a research report on Wednesday, September 25th. BTIG Research boosted their target price on shares of Insulet from $250.00 to $260.00 and gave the company a "buy" rating in a research report on Monday. Piper Sandler upped their price objective on shares of Insulet from $230.00 to $285.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 17th. Finally, UBS Group upped their price objective on shares of Insulet from $211.00 to $223.00 and gave the stock a "neutral" rating in a research report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, Insulet has a consensus rating of "Moderate Buy" and a consensus price target of $242.29.

Insulet Price Performance

Shares of NASDAQ:PODD traded down $1.47 during midday trading on Thursday, hitting $229.13. The stock had a trading volume of 309,453 shares, compared to its average volume of 798,476. The company's 50-day moving average price is $217.11 and its 200-day moving average price is $196.34. The company has a market capitalization of $16.05 billion, a P/E ratio of 69.43, a price-to-earnings-growth ratio of 4.34 and a beta of 1.21. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. Insulet has a fifty-two week low of $128.68 and a fifty-two week high of $243.98.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.56 by ($0.01). The business had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. Insulet had a net margin of 21.11% and a return on equity of 30.73%. The business's revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.38 EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in Insulet by 3.0% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,453 shares of the medical instruments supplier's stock worth $1,502,000 after buying an additional 188 shares during the last quarter. Cabot Wealth Management Inc. raised its holdings in Insulet by 1.7% during the third quarter. Cabot Wealth Management Inc. now owns 15,983 shares of the medical instruments supplier's stock worth $3,720,000 after buying an additional 262 shares during the last quarter. Swedbank AB raised its holdings in Insulet by 3.2% during the third quarter. Swedbank AB now owns 21,232 shares of the medical instruments supplier's stock worth $4,942,000 after buying an additional 655 shares during the last quarter. Ayrshire Capital Management LLC acquired a new position in Insulet during the third quarter worth $3,975,000. Finally, Shaker Investments LLC OH purchased a new stake in shares of Insulet in the third quarter valued at about $2,563,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.